Log In Get Started
Press Releases May 12, 2026 06:10 PM

Aeluma to Participate in Upcoming Investor Conferences

Aeluma to Present at LD Micro Invitational XVI Investor Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ALMU

Aeluma, Inc., a NASDAQ-listed semiconductor company specializing in high-performance technologies across multiple advanced sectors, announced its participation in the LD Micro Invitational XVI on May 19, with a live webcast presentation by its CEO and CFO.

Aeluma to Participate in Upcoming Investor Conferences
ALMU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aeluma focuses on scalable semiconductor technologies for sectors including mobile, AI, defense, aerospace, robotics, automotive, AR/VR, and quantum computing.
  • The company will present at the LD Micro Invitational XVI investor conference, providing an opportunity to update investors on its strategy and developments.
  • The presentation is accessible via live webcast, increasing reach to investors and stakeholders.

GOLETA, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, today announced that it will participate in the following upcoming investor conferences:

  • LD Micro Invitational XVI at the Luxe Sunset Boulevard Hotel in Los Angeles on Tuesday, May 19. Aeluma CEO Jonathan Klamkin and CFO Christopher Stewart will present at 10am PT. Interested parties are invited to watch the live webcast presentation via the conference website or the 

Risks

  • The article does not provide new financial results or product announcements, limiting immediate impact on stock valuation.
  • Market conditions and ongoing competition in the semiconductor industry remain uncertainties affecting company performance.
  • Investor reception to the presentation content is unknown and could influence stock price post-event.

More from Press Releases

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026